Overview:
Chronic Fatigue Syndrome ProfileIntroduction: The Chronic Fatigue Syndrome Profile is a diagnostic tool designed to screen for chronic fatigue causes using serum and whole blood samples. Associated with conditions like chronic fatigue syndrome, hypothyroidism, and viral infections, these disorders present with persistent fatigue, cognitive impairment, and severe complications if untreated, particularly in individuals with chronic fatigue symptoms. Per the 2023 Biochemistry, Hematology, and Serology guidelines, the test employs biochemistry, hematology, and serology with immunoassay and automated cell counter technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for fatigue evaluation in clinical settings. This diagnostic falls under fatigue evaluation and targets individuals with suspected chronic fatigue, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.
Other Names: CFS Pfl.
FDA Status: FDA approved, CLIA certified for biochemistry, hematology, and serology, compliant with 2025 standards.
Historical Milestone: Introduced in the 1990s by clinical labs, this test advanced fatigue diagnostics.
Purpose: The test screens for 49 parameters including hemoglobin to guide fatigue assessment, assess metabolic, inflammatory, and infectious status, and inform treatment and prevention strategies.
Test Parameters: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. Differential Count, 6. ESR, 7. CRP, 8. TSH, 9. Free T4, 10. Free T3, 11. Cortisol, 12. Vitamin B12, 13. Folate, 14. Ferritin, 15. Iron, 16. TIBC, 17. Transferrin Saturation, 18. Vitamin D, 19. Magnesium, 20. Calcium, 21. Phosphorus, 22. EBV IgG, 23. EBV IgM, 24. CMV IgG, 25. CMV IgM, 26. ANA, 27. Anti-dsDNA, 28. Rheumatoid Factor, 29. Total Protein, 30. Albumin, 31. Globulin, 32. Creatinine, 33. Urea, 34. Uric Acid, 35. Total Bilirubin, 36. AST, 37. ALT, 38. ALP, 39. Sodium, 40. Potassium, 41. Chloride, 42. Glucose, 43. HbA1c, 44. Total Cholesterol, 45. HDL, 46. LDL, 47. Triglycerides, 48. D-Dimer, 49. Lactate.
Pretest Condition: No fasting required; patients should report persistent fatigue or cognitive impairment.
Specimen: 3 mL serum in 1 SST, 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours (Serum), 48 hours (Blood) with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days (Serum, Blood) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months (Serum) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on persistent fatigue, cognitive impairment, prior fatigue reactions, or family history of chronic conditions, as well as any recent trauma or treatments.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated chronic fatigue including disability, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves sample processing using immunoassay and automated cell counter and interpret results within 1-2 days using provided controls.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate possible chronic fatigue causes, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early stages.
Specialist Consultation: General practitioners or specialists in endocrinology or infectious disease should be consulted for case management, treatment planning, and coordination with health programs.
Additional Supporting Tests: Sleep study or viral load testing for confirmation.
Test Limitations: The test may produce false negatives in early disease stages or false positives in acute inflammation, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: Biochemistry, Hematology, and Serology Guidelines 2023, Journal of Fatigue Research 2024, Immunology 2025.
